Related Experiment Video
Updated: Jul 15, 2025

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
Transcatheter aortic valve replacement outcomes in patients with low-flow very low-gradient aortic stenosis
Hiroki A Ueyama1,2,3, Lakshay Chopra1,2, Ankur Dalsania1
1Division of Cardiology, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029, USA.
Insights
Patients with severe aortic stenosis and very low-flow low-gradient (LG) have worse outcomes. Transcatheter aortic valve replacement (TAVR) did not show benefit in this distinct population, indicating a need for further research.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Severe aortic stenosis (AS) with low-flow low-gradient (LG) is associated with poor prognosis.
- Very low-flow LG (mean pressure gradient ≤ 20 mmHg) may indicate a unique patient subgroup with advanced cardiac dysfunction.
Purpose of the Study:
- To characterize patients with very low-flow LG severe AS.
- To evaluate the clinical outcomes and TAVR benefit in this specific AS population.
Main Methods:
- Single-center retrospective study of 662 patients with low-flow severe AS (2019-2021).
- Patients categorized into very LG (MPG ≤ 20 mmHg), LG (20 < MPG < 40 mmHg), and high-gradient (HG) (MPG ≥ 40 mmHg) groups.
- Comparison of composite endpoint (all-cause mortality, heart failure rehospitalization) between groups and after TAVR versus conservative management.
Main Results:
- The very LG cohort (20%) exhibited higher comorbidities and lower LVEF (45%) compared to LG (51%) and HG (29%) groups.
- A graded increase in adverse events was observed with decreasing MPG.
- In TAVR recipients, very LG was an independent predictor of adverse outcomes (aHR 2.42).
- TAVR reduced adverse events in LG and HG groups but not in the very LG group (aHR 0.69).
Conclusions:
- Very low-flow LG severe AS defines a distinct patient group with substantial comorbidities and poorer outcomes.
- Transcatheter aortic valve replacement (TAVR) does not appear to confer a survival or rehospitalization benefit in this specific subgroup.
- Further research is required to ascertain the optimal management strategy and TAVR efficacy in patients with very low-flow LG severe AS.
Aims:
In patients with severe aortic stenosis (AS), low-flow low-gradient (LG) is a known predictor of worse outcomes. However, very LG may represent a distinct population with further cardiac dysfunction. It is unknown whether this population benefits from transcatheter aortic valve replacement (TAVR). We aimed to describe the patient characteristics and clinical outcomes of low-flow very LG severe AS.
Methods And Results:
This single-centre study included all patients with low-flow severe AS between 2019 and 2021. Patients were divided into groups with very LG [mean pressure gradient (MPG) ≤ 20 mmHg], LG (20 < MPG < 40 mmHg), and high-gradient (HG) (MPG ≥ 40 mmHg). Composite endpoint of all-cause mortality and heart failure rehospitalization was compared. A total of 662 patients [very LG 130 (20%); LG 339 (51%); HG 193 (29%)] were included. Median follow-up was 12 months. Very LG cohort had a higher prevalence of comorbid conditions with lower left ventricular ejection fraction (45% vs. 57% vs. 60%; P < 0.001). There was a graded increase in the risk of composite endpoint in the lower MPG strata (P < 0.001). Among those who underwent TAVR, very LG was an independent predictor of the composite endpoint (adjusted HR 2.42 [1.29-4.55]). While LG and HG cohorts had decreased risk of composite endpoint after TAVR compared with conservative management, very LG was not associated with risk reduction (adjusted HR 0.69 [0.35-1.34]).
Conclusion:
Low-flow very LG severe AS represents a distinct population with significant comorbidities and worse outcomes. Further studies are needed to evaluate the short- and long-term benefits of TAVR in this population.
More Related Videos
Related Concept Videos
Mitral Stenosis III: Medical Management
Aortic Regurgitation III: Medical Management
Aortic Regurgitation IV: Nursing Management
Mitral Stenosis IV: Nursing Management

